AIRWAY THERAPEUTICS
Airway Therapeutics is an early stage development company that is licensing technology from within the pulmonary research program of Cincinnati Children's Hospital Medical Center (CCHMC) for further technology platform development. This platform will enable the development of three or more products that address various market needs in the overall market for lung disorders.
AIRWAY THERAPEUTICS
Industry:
Biotechnology Health Care Medical Device Pharmaceutical
Founded:
2011-01-01
Address:
Cincinnati, Ohio, United States
Country:
United States
Website Url:
http://www.airwaytherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
513 770 9630
Email Addresses:
[email protected]
Total Funding:
38.78 M USD
Technology used in webpage:
CrUX Dataset Person Schema CrUX Top 50m Gravatar Profiles
Similar Organizations
Braeburn
Braeburn is dedicated to delivering solutions for people living with the serious consequences of opioid use disorder.
Echo Therapeutics
Echo Therapeutics develops the Symphony tCGM System, a novel, non-invasive (needle-free) glucose monitoring system for diabetes patients.
Instadiagnostics
Instadiagnostics Inc., is developing a rapid, quantitative, point-of-care (POC) diagnostic platform.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Osciflex
Osciflex system imitates nature’s process to prevent deadly blood clots.
Strados Labs
Strados Labs innovates respiratory monitoring using smart biosensors and artificial intelligence.
Current Advisors List
Current Employees Featured
Founder
Investors List
Queen City Angels
Queen City Angels investment in Series C - Airway Therapeutics
Cincinnati Children’s
Cincinnati Children’s investment in Series C - Airway Therapeutics
CincyTech
CincyTech investment in Series C - Airway Therapeutics
Danmar Capital
Danmar Capital investment in Series C - Airway Therapeutics
Queen City Angels
Queen City Angels investment in Series B - Airway Therapeutics
Cincinnati Children’s
Cincinnati Children’s investment in Series B - Airway Therapeutics
Danmar Capital
Danmar Capital investment in Series B - Airway Therapeutics
CincyTech
CincyTech investment in Convertible Note - Airway Therapeutics
Queen City Angels
Queen City Angels investment in Convertible Note - Airway Therapeutics
Cincinnati Children’s
Cincinnati Children’s investment in Convertible Note - Airway Therapeutics
Newest Events participated
Participated in 2017 CincyTech Big Breakfast + Startup Showcase
on 2017-11-08 as exhibitor
Official Site Inspections
http://www.airwaytherapeutics.com
- Host name: 120.223.135.34.bc.googleusercontent.com
- IP address: 34.135.223.120
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Airway Therapeutics"
Company History- About Us - Airway Therapeutics
Our Mission Airway Therapeutics is a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases. The company is advancing the …See details»
Airway Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Phone Number 513 770 9630 Airway Therapeutics is an early stage development company that is licensing technology from within the pulmonary research program of Cincinnati …See details»
Airway Therapeutics - LinkedIn
Airway Therapeutics | 1,087 followers on LinkedIn. Developing a new class of biologics for patients with respiratory and inflammatory diseases. | Created in 2011 as a spin-out of Cincinnati ...See details»
Airway Therapeutics Joins C-Path’s International Neonatal …
Feb 15, 2023 To learn more, visit https://www.airwaytherapeutics.com. Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private …See details»
Airway Therapeutics, Inc. | Ohio Life Sciences
Airway Therapeutics, Inc. was created in 2011 as a spin-out of Cincinnati Children's Hospital Medical Center (CCHMC), and has extensive expertise in protein development for applications …See details»
THE LATEST NEWS - Airway Therapeutics
Airway Therapeutics to Launch a Multinational Phase 3 Trial of Zelpultide Alfa for Preterm Neonates at Risk of Bronchopulmonary Dysplasia . October 15, 2024 05:30 AM Eastern …See details»
Airway Therapeutics Opens International Clinical Trial Sites and …
Oct 3, 2022 Zelpultide alfa has been approved as the generic name for our AT-100 (rhSP-D) by the two governing organizations, the United States Adopted Names (USAN) Council and the …See details»
Airway Therapeutics Company Profile 2024: Valuation, Funding ...
Information on valuation, funding, cap tables, investors, and executives for Airway Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Airway Therapeutics Announces FDA Acceptance of IND for AT
Mar 26, 2021 https://www.airwaytherapeutics.com. × Modal title. Organization Profile. Airway Therapeutics, Inc. Contact Cision. 866-245-2317 from 8 AM - 10 PM ET Contact UsSee details»
Airway Therapeutics Announces First Patient Dosed in Phase 1b …
CINCINNATI, Aug. 26, 2021 /PRNewswire/ -- Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics to break the cycle of injury …See details»
Airway Therapeutics - Overview, News & Similar companies
Airway Therapeutics contact info: Phone number: (513) 770-9630 Website: www.airwaytherapeutics.com What does Airway Therapeutics do? Airway Therapeutics is a …See details»
Airway Therapeutics Closes $15.5 Million Series C ... - Business Wire
Jan 8, 2020 Sandra Roberts [email protected] P: 513-770-9630 Release Summary. Airway Therapeutics raises $15.5M to advance research and development of …See details»
Airway Therapeutics, Inc
Jan 8, 2020 Airway’s first candidate AT-100 is in development for the prevention of bronchopulmonary dysplasia (BPD) in very preterm infants. To learn more, visit …See details»
| Airway Therapeutics
Company plans to initiate a multinational pivotal trial of zelpultide alfa (rhSP-D) in Q4/2024 beginning in Europe. The study will enroll more than 300 neonates born at 23 weeks to 27 …See details»
Airway Therapeutics Announces First Patient Dosed in Phase 1b …
Novel therapeutic AT-100 offers potential to reduce inflammation, associated injury and incidence of secondary infection, and inhibit viral replication and promote viral elimination in severely ill, …See details»
Airway Therapeutics Completes Dose Escalation in Phase 1b Trial …
Apr 11, 2023 Meghan Riley [email protected] Release Summary Airway Therapeutics completes dose escalation in Phase 1b trial of Zelpultide Alfa for very preterm …See details»
Airway Therapeutics Announces FDA Acceptance of IND for AT …
Apr 12, 2021 Initiating Phase 1b clinical trial with initial results expected 3Q2021. Potential for novel therapeutic AT-100 to inhibit viral replication, promote viral elimination and reduction of …See details»
Airway Therapeutics Announces Filing with NIH to Evaluate AT …
Mar 11, 2020 Data demonstrate AT-100 (rhSP-D) – novel human recombinant protein – reduces infection in a range of bacteria and virus-driven respiratory diseases with potential to treat …See details»
Airway Therapeutics Announces First Patient Dosed in Phase 1b …
Mar 31, 2022 Novel preventative AT-100 offers potential to reduce incidence and severity of serious respiratory disease BPD, improving outcomes in very preterm infants. MARIETTA, …See details»